{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:04:13Z","timestamp":1780113853524,"version":"3.54.0"},"reference-count":35,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2026,5,30]]},"DOI":"10.1536\/ihj.25-278","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:09:26Z","timestamp":1780092566000},"page":"253-264","source":"Crossref","is-referenced-by-count":0,"title":["Finerenone Attenuates Myocardial Fibrosis and Pyroptosis in Rats with Myocardial Infarction"],"prefix":"10.1536","volume":"67","author":[{"given":"Jing","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Guilin Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-chun","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Guilin Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-hong","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-qi","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Guilin Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-min","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Guilin Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-yi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Guilin Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27: 1281-92.","DOI":"10.1016\/S0022-2828(05)82390-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Warren SE, Royal HD, Markis JE, Grossman W, McKay RG. Time course of left ventricular dilation after myocardial infarction: influence of infarct-related artery and success of coronary thrombolysis. J Am Coll Cardiol 1988; 11: 12-9.","DOI":"10.1016\/0735-1097(88)90159-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lew WY, Chen ZY, Guth B, Covell JW. Mechanisms of augmented segment shortening in nonischemic areas during acute ischemia of the canine left ventricle. Circ Res 1985; 56: 351-8.","DOI":"10.1161\/01.RES.56.3.351"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Anderson JL, Morrow DA. Acute Myocardial Infarction. N Engl J Med 2017; 376: 2053-64.","DOI":"10.1056\/NEJMra1606915"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Jiang H, Fang T, Cheng Z. Mechanism of heart failure after myocardial infarction. J Int Med Res 2023; 51: 3000605231202573.","DOI":"10.1177\/03000605231202573"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends Biochem Sci 2017; 42: 245-54.","DOI":"10.1016\/j.tibs.2016.10.004"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Takahashi M. Cell-Specific Roles of NLRP3 Inflammasome in Myocardial Infarction. J Cardiovasc Pharmacol 2019; 74: 188-93.","DOI":"10.1097\/FJC.0000000000000709"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Kayagaki N, Stowe IB, Lee BL, <i>et al<\/i>. Caspase-11 cleaves gasdermin D for noncanonical inflammasome signaling. Nature 2015; 526: 666-71.","DOI":"10.1038\/nature15541"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Li Z, Liu W, Fu J, <i>et al<\/i>. Shigella evades pyroptosis by arginine ADP-riboxanation of caspase-11. Nature 2021; 599: 290-5.","DOI":"10.1038\/s41586-021-04020-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sandanger \u00d8, Ranheim T, Vinge LE, <i>et al<\/i>. The NLRP3 inflammasome is upregulated in cardiac fibroblasts and mediates myocardial ischemia-reperfusion injury. Cardiovasc Res 2013; 99: 164-74.","DOI":"10.1093\/cvr\/cvt091"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Al-Hashedi EM, Abdu FA. Aldosterone Effect on Cardiac Structure and Function. Curr Cardiol Rev 2024; 20: 60-7.","DOI":"10.2174\/011573403X281390240219063817"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pitt B, Pedro Ferreira J, Zannad F. Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. Eur Heart J Cardiovasc Pharmacother 2017; 3: 48-57.","DOI":"10.1093\/ehjcvp\/pvw016"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jaisser F, Farman N. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology. Pharmacol Rev 2016; 68: 49-75.","DOI":"10.1124\/pr.115.011106"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Zhang Y, Jiang L, Wang J, Wu X. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol 2022; 21: 232.","DOI":"10.1186\/s12933-022-01676-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. B\u00e4rfacker L, Kuhl A, Hillisch A, <i>et al<\/i>. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. Chem Med Chem 2012; 7: 1385-403.","DOI":"10.1002\/cmdc.201200081"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. DuPont JJ, Jaffe IZ. 30 years of the mineralocorticoid receptor: The role of the mineralocorticoid receptor in the vasculature. J Endocrinol 2017; 234: T67-82.","DOI":"10.1530\/JOE-17-0009"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Wendl T, Frechen S, Gerisch M, <i>et al<\/i>. Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone. CPT Pharmacometrics Syst Pharmacol 2022; 11: 199-211.","DOI":"10.1002\/psp4.12746"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Liu LC, Schutte E, Gansevoort RT, van der Meer P, Voors AA. Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs 2015; 24: 1123-35.","DOI":"10.1517\/13543784.2015.1059819"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Jin T, Fu X, Liu M, An F. Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus. Diabetol Metab Syndr 2023; 15: 87.","DOI":"10.1186\/s13098-023-01064-3"},{"key":"20","unstructured":"20. Li J, Zhong G, Wei Z, <i>et al<\/i>. Establishment of a rat myocardial infarction model and changes in electrophysiology and left ventricular function after infarction. Acta Laboratorium Animalis Scientia Sinica 2009; 17: 419-23, 397-8."},{"key":"21","unstructured":"21. Bayer AG. Kerendia (finerenone) prescribing information. U.S. Food and Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215341s000lbl.pdf. Accessed April 8, 2026."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer 2022; 21: 104.","DOI":"10.1186\/s12943-022-01569-x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Grune J, Beyhoff N, Smeir E, <i>et al<\/i>. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone&apos;s Antifibrotic Activity. Hypertension 2018; 71: 599-608.","DOI":"10.1161\/HYPERTENSIONAHA.117.10360"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Dewidar B, Meyer C, Dooley S, Meindl-Beinker AN. TGF-\u03b2 in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. Cells 2019; 8: 1419.","DOI":"10.3390\/cells8111419"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chen G, Ge D, Zhu B, Shi H, Ma Q. Upregulation of matrix metalloproteinase 9 (MMP9) \/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2\/TIMP2 ratios may be involved in lipopolysaccharide-induced acute lung injury. J Int Med Res 2020; 48: 300060520919592.","DOI":"10.1177\/0300060520919592"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Bruckert C, Matsushita K, Mroueh A, <i>et al<\/i>. Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: Role of endothelial SGLT1 and 2. Vascul Pharmacol 2022; 146: 107095.","DOI":"10.1016\/j.vph.2022.107095"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Jia C, Chen H, Zhang J, <i>et al<\/i>. Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol 2019; 67: 311-8.","DOI":"10.1016\/j.intimp.2018.12.028"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Chai R, Ye Z, Xue W, <i>et al<\/i>. Tanshinone IIA inhibits cardiomyocyte pyroptosis through TLR4\/NF-\u03baB p65 pathway after acute myocardial infarction. Front Cell Dev Biol 2023; 11: 1252942.","DOI":"10.3389\/fcell.2023.1252942"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Filippatos G, Anker SD, B\u00f6hm M, <i>et al<\/i>. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J 2016; 37: 2105-14.","DOI":"10.1093\/eurheartj\/ehw132"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sinphitukkul K, Manotham K, Eiam-Ong S, <i>et al<\/i>. Aldosterone nongenomically induces angiotensin II receptor dimerization in rat kidney: role of mineralocorticoid receptor and NADPH oxidase. Arch Med Sci 2019; 15: 1589-98.","DOI":"10.5114\/aoms.2019.87135"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Luther JM, Fogo AB. The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis. Kidney Int Suppl 2022; 12: 63-8.","DOI":"10.1016\/j.kisu.2021.11.006"},{"key":"32","unstructured":"32. Lin Z, Lu Y, Li S, <i>et al<\/i>. Effect of eplerenone on cognitive impairment in spontaneously hypertensive rats. Am J Transl Res 2022; 14: 3864."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Hirai T, Ueda S, Ogura T, <i>et al<\/i>. Hyperkalemia by eplerenone or esaxerenone in the presence or absence of clarithromycin in hypertensive patients: a retrospective observational cohort study. J Hypertens 2023; 41: 580-6.","DOI":"10.1097\/HJH.0000000000003372"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Pandey AK, Bhatt DL, Cosentino F, <i>et al<\/i>. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J 2022; 43: 2931-45.","DOI":"10.1093\/eurheartj\/ehac299"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 2022; 179: 3220-34.","DOI":"10.1111\/bph.15747"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/3\/67_25-278\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:31:04Z","timestamp":1780111864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/3\/67_25-278\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.25-278","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"article-number":"25-278"}}